This Phase IIb initiation is a material clinical milestone for a micro-cap biotech with limited visibility; traders should monitor upcoming enrollment updates and safety/efficacy data reads in 6–9 months. A successful trial could position PBM for partnership or licensing interest.
Price Chart
Executive Summary
Psyence Biomedical Ltd. (PBM) announced the first patient dosed in its Phase IIb clinical trial evaluating NPX-5, a nature-derived psilocybin candidate, for Adjustment Disorder in cancer patients in palliative care. This marks the company’s transition into active human data generation across its Australian clinical network and represents a key milestone in its psychedelic therapeutic development program.
Key Facts
- First patient dosed in Phase IIb trial of NPX-5 (25mg psilocybin) for Adjustment Disorder in palliative cancer patients.
- Trial is randomized, double-blind, three-arm study across five clinical sites in Australia.
- Primary objectives include assessing clinical response, symptom reduction, safety, and treatment durability.
- NPX-5 is GMP-compliant and part of a vertically integrated development platform via PsyLabs.
- Company is focused on generating high-quality data to inform future regulatory pathways.
Financial Impact
No immediate direct financial impact, but de-risks clinical development path
Risk Factors
- Clinical trial may face delays in enrollment or site execution
- Safety or efficacy signals could negatively impact development
- Limited cash runway or financing risk given small market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3279726 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers